Human–Animal Embryo Chimeras Fail; Vaccines Do Not Cause Autism; Potatoes Being Genetically Modified to Resist Blight; Gene Therapy May Be Useful Against HIV; Cell Therapy for Fractures?; Improving Radiosensitivity of Cancer; Rheumatoid Arthritis Patients Benefit from Gene Therapy; Fetal Stem Cell Therapy Leads to Tumors; Possible Nanotechnology Utility for Glucose Monitoring

2009 ◽  
Vol 28 (2) ◽  
pp. 183-186
2022 ◽  
Vol 15 ◽  
Author(s):  
Li Zhang ◽  
Sen Chen ◽  
Yu Sun

Sensorineural hearing loss (SNHL) is one of the most prevalent sensory deficits in humans, and approximately 360 million people worldwide are affected. The current treatment option for severe to profound hearing loss is cochlear implantation (CI), but its treatment efficacy is related to the survival of spiral ganglion neurons (SGNs). SGNs are the primary sensory neurons, transmitting complex acoustic information from hair cells to second-order sensory neurons in the cochlear nucleus. In mammals, SGNs have very limited regeneration ability, and SGN loss causes irreversible hearing loss. In most cases of SNHL, SGN damage is the dominant pathogenesis, and it could be caused by noise exposure, ototoxic drugs, hereditary defects, presbycusis, etc. Tremendous efforts have been made to identify novel treatments to prevent or reverse the damage to SGNs, including gene therapy and stem cell therapy. This review summarizes the major causes and the corresponding mechanisms of SGN loss and the current protection strategies, especially gene therapy and stem cell therapy, to promote the development of new therapeutic methods.


2014 ◽  
pp. 83-100
Author(s):  
Jennifer Ryan ◽  
Michael Ting ◽  
Nicholas Fisk

Sign in / Sign up

Export Citation Format

Share Document